Merck Animal Health’s Numelvi Secures the FDA Approval for Control of Pruritus Associated with Allergic Dermatitis in Dogs

Shots:

• The US FDA has approved Numelvi (Atinvicitinib) for the control of pruritus associated with allergic dermatitis in dogs (≥6mos.), with availability expected in spring 2026
• Numelvi is a second-generation JAK inhibitor supplied in easy-to-dispense bottles and designed for convenient storage under standard conditions.
• Numelvi is ≥10-fold more selective for JAK1 over JAK2, JAK3 & TYK2 in vitro, inhibiting JAK1-dependent cytokines that drive itch & inflammation in allergic dermatitis, incl. atopic dermatitis, with a high selectivity supporting efficacy & a favorable safety profile

Ref: Businesswire  |   Image: Merck Animal Health   |   Press Release

Related News: Merck Animal Health’s Exzolt Cattle-CA1 Receives the US FDA Conditional Approval Against New World Screwworm and Cattle Fever Tick

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com